CN118638211A - 基因工程改造获得的分泌能力和凝血活性增强的人类八因子 - Google Patents

基因工程改造获得的分泌能力和凝血活性增强的人类八因子 Download PDF

Info

Publication number
CN118638211A
CN118638211A CN202410604831.3A CN202410604831A CN118638211A CN 118638211 A CN118638211 A CN 118638211A CN 202410604831 A CN202410604831 A CN 202410604831A CN 118638211 A CN118638211 A CN 118638211A
Authority
CN
China
Prior art keywords
fviii
hfviii
domain
human
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410604831.3A
Other languages
English (en)
Chinese (zh)
Inventor
董飚
张波
叶静娅
肖�琳
郑赵悦
杨荔
刘瑜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Zhishan Weixin Biotechnology Co ltd
Original Assignee
Sichuan Zhishan Weixin Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Zhishan Weixin Biotechnology Co ltd filed Critical Sichuan Zhishan Weixin Biotechnology Co ltd
Publication of CN118638211A publication Critical patent/CN118638211A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202410604831.3A 2021-11-25 2022-02-11 基因工程改造获得的分泌能力和凝血活性增强的人类八因子 Pending CN118638211A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021133004 2021-11-25
CNPCT/CN2021/133004 2021-11-25
PCT/CN2022/075976 WO2023092864A1 (en) 2021-11-25 2022-02-11 Engineered human fviii with enhanced secretion ability and clotting activity
CN202280001407.9A CN116710554B (zh) 2021-11-25 2022-02-11 基因工程改造获得的分泌能力和凝血活性增强的人类八因子

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280001407.9A Division CN116710554B (zh) 2021-11-25 2022-02-11 基因工程改造获得的分泌能力和凝血活性增强的人类八因子

Publications (1)

Publication Number Publication Date
CN118638211A true CN118638211A (zh) 2024-09-13

Family

ID=84487686

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410604831.3A Pending CN118638211A (zh) 2021-11-25 2022-02-11 基因工程改造获得的分泌能力和凝血活性增强的人类八因子
CN202410604829.6A Pending CN118546234A (zh) 2021-11-25 2022-02-11 基因工程改造获得的分泌能力和凝血活性增强的人类八因子
CN202280001407.9A Active CN116710554B (zh) 2021-11-25 2022-02-11 基因工程改造获得的分泌能力和凝血活性增强的人类八因子

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410604829.6A Pending CN118546234A (zh) 2021-11-25 2022-02-11 基因工程改造获得的分泌能力和凝血活性增强的人类八因子
CN202280001407.9A Active CN116710554B (zh) 2021-11-25 2022-02-11 基因工程改造获得的分泌能力和凝血活性增强的人类八因子

Country Status (5)

Country Link
US (1) US20240254197A1 (cg-RX-API-DMAC7.html)
EP (1) EP4211153A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024544499A (cg-RX-API-DMAC7.html)
CN (3) CN118638211A (cg-RX-API-DMAC7.html)
WO (1) WO2023092864A1 (cg-RX-API-DMAC7.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
EP1985631A1 (en) * 2007-04-20 2008-10-29 LFB Biotechnologies Demannosylated recombinant factor VIII for the treatment of patients with hemophiila A
WO2013123457A1 (en) * 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
HRP20210031T1 (hr) * 2013-06-24 2021-05-14 Weidong, Xiao Pripravci i metode mutantskog faktora viii
US20160311885A1 (en) * 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
ES2819123T3 (es) * 2015-01-30 2021-04-15 Univ Emory Proteínas del factor VIII que tienen secuencias ancestrales, vectores de expresión, y usos relacionados con ellos
CN108884145B (zh) * 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
KR102219859B1 (ko) * 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
JP2020519272A (ja) * 2017-05-09 2020-07-02 エモリー ユニバーシティー 凝固因子変異体及びその使用
TWI851647B (zh) * 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2022165390A1 (en) * 2021-01-29 2022-08-04 Expression Therapeutics, Llc Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use

Also Published As

Publication number Publication date
CN118546234A (zh) 2024-08-27
CN116710554B (zh) 2024-06-07
TW202321290A (zh) 2023-06-01
WO2023092864A1 (en) 2023-06-01
JP2024544499A (ja) 2024-12-03
US20240254197A1 (en) 2024-08-01
EP4211153A4 (en) 2023-11-01
CN116710554A (zh) 2023-09-05
EP4211153A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
ES2958832T3 (es) Plásmido que contiene una secuencia que codifica para un ARNm con una cola de poli(A) segmentada
ES2732774T3 (es) UTR que aumentan la eficacia de la traducción de las moléculas de ARN
EP3052521A1 (en) Polynucleotides encoding low density lipoprotein receptor
TW202239762A (zh) 桿狀病毒表現系統
US20250257368A1 (en) In vitro assembly of anellovirus capsids enclosing rna
US20230045478A1 (en) Liver-specific promoter and application thereof
US20230227849A1 (en) Methods of identifying and characterizing anelloviruses and uses thereof
CN119421716A (zh) 用于环状rna亲和纯化的组合物和方法
CN114929872A (zh) 用nadh脱氢酶蛋白治疗莱伯遗传性视神经病变的组合物和方法
CN111718947A (zh) 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途
JP2024532596A5 (cg-RX-API-DMAC7.html)
CN110331147A (zh) 一种mRNA的制备方法及其在肿瘤治疗中的应用
US20240417751A1 (en) Rna replicon for improving gene expression and use thereof
WO2024230802A1 (en) Engineered liver-specific core promoters and their applications
CN116710554B (zh) 基因工程改造获得的分泌能力和凝血活性增强的人类八因子
RU2852567C2 (ru) Сконструированный полипептид человеческого фактора VIII (hFVIII) с повышенной коагулирующей активностью, фрагмент выделенной нуклеиновой кислоты, вектор экспрессии (варианты), фармацевтическая композиция для лечения гемофилии A и способ ее лечения
TWI893802B (zh) 工程化的肝臟特異性增強子、核心啟動子及其應用
US20250121096A1 (en) Engineered liver-specific enhancers and their applications
CN116590298A (zh) 一种编码人hgf的核酸及其应用
HK40120431A (en) Engineered liver-specific core promoters and their applications
CN119685289A (zh) 一种用于调控CaMKII-δ亚型选择性表达的单碱基编辑系统
CN112695032A (zh) 一种启动子pLRRK2及其应用
CN120683113A (zh) 抗纤维化的saRNA-Rplp0疫苗及其制备方法和应用
WO2023283749A1 (zh) 一种迷你启动子pCALM1及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination